ArticleJournal of functional biomaterials2026
Synthesis and Characterization of Modified Chitosan Materials with Assessment of Their Antibacterial and Antiviral Activities.
Article in Journal of functional biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modified chitosan (Cs) derivatives were synthesized and evaluated as potential antibacterial and antiviral coatings of medical protective equipment (facial masks, gloves, …). Quaternized chitosan (HTCC) and chitosan-silver nanocomposites (Ag/Cs) were successfully prepared, with structural characterization confirming efficient quaternization and uniform incorporation of silver nanoparticles. Antibacterial testing revealed that HTCC exhibited concentration-dependent activity, while Ag/Cs showed strong broad-spectrum antibacterial effects and enhanced thermal stability. Antiviral assays against SARS-CoV-2 demonstrated significant viral inhibition for HTCC6 and Ag/Cs at non-cytotoxic concentrations (6 mg/mL), highlighting the role of cationic charge and nanoparticle inclusion in antiviral efficacy. These findings indicate that the developed chitosan derivatives are promising candidates for sustainable functional coatings on medical devices, offering potential applications in infection prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.